News

Tufts CSDD finds drug and diagnostics companies are investing in the development of companion diagnostics that can show that their use in conjunction with personalized therapeutics will lead to positive health outcomes.

An analysis by Life Science Compliance Update of the U.S. government's Open Payments database shows that industry spending on U.S-based clinical research has dropped 32% in the first year-over-year comparison since Open Payments data started to be collected.